Abstract 231P
Background
Pembrolizumab monotherapy has shown antitumor activity and acceptable safety in patients with mCRPC previously treated with a next-generation hormonal agent (NHA) and docetaxel.
Methods
The KEYNOTE-199 phase II study (NCT02787005) enrolled patients with RECIST-measurable PD-L1+ disease, RECIST-measurable PD-L1− disease, and bone-predominant disease irrespective of PD-L1 status in C1, C2, and C3, respectively. Patients had prior treatment with ≥1 NHA and 1 or 2 chemotherapies, including docetaxel, and received pembrolizumab 200 mg Q3W for 35 cycles or until progression/toxicity. The primary end point was ORR per RECIST v1.1 by blinded independent central review. Key secondary end points were time to PSA progression, DCR, PSA response rate, rPFS, OS, DOR, and safety.
Results
In total, 258 patients were treated (C1: 133; C2: 67; C3: 58), of whom 6 completed therapy (C1: 4; C3: 2). The median (range) time from enrollment to data cutoff was 31.3 mo (26.7-34.7), 30.6 mo (28.0-34.1), and 32.6 mo (27.4-34.4) in C1, C2, and C3, respectively. In patients with measurable disease, ORR (95% CI) was 6% (2.6-11.5) in C1 and 3% (0.4-10.4) in C2, and 6 of 10 responders experienced DOR ≥18 mo (Table). Median time to PSA progression was 4 mo regardless of cohort (Table). Grade ≥3 treatment-related AEs (TRAEs) occurred in 16%, 15%, and 17% of patients in C1, C2, and C3, respectively (1 death in each cohort from a TRAE [C1: sepsis; C2: unknown; C3: immune-related pneumonitis]). Table: 231P
Efficacy outcomes
Cohort 1 Measurable, PD-L1+ n = 133 | Cohort 2 Measurable, PD-L1− n = 67 | Cohort 3 Bone Predominant n = 58 | |
ORR per RECIST v1.1 per BICR, measurable disease, n/N (%) | 8/133 (6) | 2/67 (3) | – |
CR, n/N (%) | 3/133 (2) | 0 | – |
PR, n/N (%) | 5/133 (4) | 2/67 (3) | – |
DCR (CR + PR + SD or non-CR/non-PD ≥6 mo), n/N (%) | 14/133 (11) | 4/67 (6) | 12/58 (21) |
PSA response rate,a pts w/baseline PSA, n/N (%) | 8/124 (6) | 5/61 (8) | 1/58 (2) |
Median time to PSA progression, mo (95% CI) | 4 (4-4) | 4 (4-6) | 4 (4-4) |
Median rPFS per PCWG3-modified RECIST, mo (95% CI) | 2 (2-2) | 2 (2-3) | 4 (2-4) |
Median OS, mo (95% CI) | 10 (6-12) | 8 (6-10) | 14 (11-18) |
OS at 24 mo, % | 22 | 16 | 21 |
a≥50% decrease from baseline.
Conclusions
In 3 cohorts of docetaxel and NHA-pretreated patients with RECIST-measurable or bone-predominant mCRPC, pembrolizumab monotherapy led to promising antitumor activity and disease control and was well tolerated. There was durable antitumor activity and disease control, with survival up to 24 mo.
Clinical trial identification
NCT02787005, June 1, 2016.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
J.C.H. Goh: Shareholder/Stockholder/Stock options: Immutep Ltd.; Honoraria (self): MSD; Advisory/Consultancy: AstraZeneca, Tesaro, BMS; Speaker Bureau/Expert testimony: Ipsen; Travel/Accommodation/Expenses: AstraZeneca, Astellas. J.M. Piulats: Advisory/Consultancy: Roche, Novartis, Jansen, Astellas, Bayer, Sanofy-Genzyme, MSD, BMS, Merk-Serono, Clovis, AstraZeneca, Beigene, VCN Biotech; Research grant/Funding (self): Roche, Jansen, Astellas, MSD, BMS, Merk-Serono, AstraZeneca, Beigene, VCN Biotech; Travel/Accommodation/Expenses: Roche, Astellas, Jansen. M. Gross-Goupil: Honoraria (self): Ipsen, Janssen, Astellas; Advisory/Consultancy: Astellas, Janssen, Ipsen, MSD; Research grant/Funding (self): MSD, BMS, Janssen, AstraZeneca, Pfizer, Roche; Travel/Accommodation/Expenses: Amgen, MSD, Roche, Pfizer, Sanofi. U.N. Vaishampayan: Advisory/Consultancy, Research grant/Funding (institution): Merck & Co., Inc. R. de Wit: Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck, Sanofi, Roche, Janssen, Clovis. T.V. Alanko: Honoraria (institution): Eli Lilly, Roche; Advisory/Consultancy: Bayer, BMS, Celgene, Eli Lilly, MSD, Nordic Drugs, Roche, Shire; Speaker Bureau/Expert testimony: Bayer, Servier; Travel/Accommodation/Expenses: BMS, Celgene, MSD, Roche, Shire. S. Fukasawa: Speaker Bureau/Expert testimony: Pfizer, Bristol-Myers Squibb, Ono Pharmaceutical, Janssen Pharmaceutical. S. Feyerabend: Advisory/Consultancy: AstraZeneca, Bayer; Travel/Accommodation/Expenses: Janssen. R. Berger: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD, BMS, AZ. H. Wu: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. J. Kim: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. C. Schloss: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. J.S. de Bono: Advisory/Consultancy: AstraZeneca, Sanofi, Astellas Pharma, Pfizer, Genentech/Roche, Janssen Oncology, Menarini Silicon Biosystems, Daiichi Sankyo, Sierra Oncology, Bayer, Merck Sharp & Dohme, Merck Serono, Boehringer Ingelheim, Celgene, Taiho Pharmaceuticals, Genmab, SlasoSmi; Research grant/Funding (institution): AstraZeneca, Genentech, Sanofi, Taiho Pharmaceuticals, Daiichi Sankyo, Merck Serono, Astex Pharmaceuticals, Merck Sharp & Dohme, Orion Pharma, GlaxoSmithKline, Cellcentric, Celgene, Sierra Oncology, Bayer, MedImmune, Medication, Terumo, Astellas Pharma, G. E.S. Antonarakis: Research grant/Funding (self): Janssen, Sanofi, Dendreon, AstraZeneca Clovis, Merck, JohnsonJohnson, Genentech, Novartis, Bristol-Myers Squibb, Eli Lilly, Tokai, Celgene; Advisory/Consultancy: Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, Merck, Eli Lilly, Amgen, Bayer, GlaxoSmithKline; Licensing/Royalties: Qiagen. All other authors have declared no conflicts of interest.
Resources from the same session
313P - Diagnostic value of micro RNA (miRNA) in renal cell cancer: A meta-analysis and systemic review
Presenter: Jestoni Aranilla
Session: e-Poster Display Session
314P - Comprehensive microbial signatures and genomic profiling in tumour samples using next generation sequencing
Presenter: Mei Qi Yee
Session: e-Poster Display Session
315P - High-penetrance breast and/or ovarian cancer susceptibility genes in Filipinos
Presenter: Frances Victoria Que
Session: e-Poster Display Session
316P - Implementation of Vela Analytics to accelerate comprehensive interpretation and reporting of next-generation sequencing-based oncology testing in clinical diagnostic laboratories
Presenter: Yingnan Yu
Session: e-Poster Display Session
317P - Genomic profiling and molecular pathology of Chinese glioma patients
Presenter: yuanli Zhao
Session: e-Poster Display Session
320P - Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies
Presenter: Kelvin Bao
Session: e-Poster Display Session
321P - Impact of COVID-19 and lockdown on adherence to treatment schedule among cancer patients
Presenter: Krishnamani Kalpathi
Session: e-Poster Display Session
322P - Challenged faced by cancer patients during the COVID-19 pandemic
Presenter: mithra Krishnamani
Session: e-Poster Display Session
323P - Oncology care in the Republic of Kazakhstan during COVID-19
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
324P - COVID era: Perception of oncologists from a developing nation
Presenter: Rakesh Roy
Session: e-Poster Display Session